Status:
TERMINATED
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
Lead Sponsor:
Oregon Health and Science University
Conditions:
Hemangioma
Infant
Eligibility:
All Genders
1-8 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. This study would examine whethe...
Detailed Description
At the first visit, subjects will fill out a questionnaire that asks about the child's history and the hemangioma. Photographs and measurements will be taken at this and each subsequent visit. At the ...
Eligibility Criteria
Inclusion
- Infants 1 month to 8 months of age with infantile hemangioma (IH) that are 3 cm or less on the scalp, trunk, or extremities.
Exclusion
- Subjects with facial, genital, perianal, hand, finger, feet, or toe IH
- Subjects with PHACES (plaque-like hemangioma on the face awaiting imaging) syndrome (proven) or suspected PHACES .
- Subjects with IH measuring more than 3cm in size or ulcerated.
- Children with a history of hypersensitivity to beta blockers.
- Children with a personal history of asthma.
- Children with known renal impairment.
- Children with known cardiac conditions that may predispose to heart block
- Personal history of hypoglycemia
- Children on medications that may interact with beta blockers
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01147601
Start Date
March 1 2010
End Date
August 1 2014
Last Update
July 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239-4501